Last reviewed · How we verify

Standard dose lamotrigine — Competitive Intelligence Brief

Standard dose lamotrigine (Standard dose lamotrigine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic drug. Area: Neurology.

marketed Anticonvulsant / Antiepileptic drug Voltage-gated sodium channels; glutamate release inhibition Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Standard dose lamotrigine (Standard dose lamotrigine) — Mario Negri Institute for Pharmacological Research. Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Standard dose lamotrigine TARGET Standard dose lamotrigine Mario Negri Institute for Pharmacological Research marketed Anticonvulsant / Antiepileptic drug Voltage-gated sodium channels; glutamate release inhibition
Lamictal TM Lamictal TM Central Mental Clinic for Outpatients of Baku City marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Brand lamotrigine Brand lamotrigine University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine generic "B" Lamotrigine generic "B" University of Cincinnati marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
lamotrigine (generic Teva) lamotrigine (generic Teva) University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Generic lamotrigine Generic lamotrigine University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
lamotrigine (brand Lamictal) lamotrigine (brand Lamictal) University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic drug class)

  1. Mario Negri Institute for Pharmacological Research · 3 drugs in this class
  2. Eisai Inc. · 2 drugs in this class
  3. Affiliated Hospital of Nantong University · 1 drug in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. MaineHealth · 1 drug in this class
  6. UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard dose lamotrigine — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dose-lamotrigine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: